United States US: Diabetes Prevalence: % of Population Aged 20-79 data was reported at 10.790 % in 2017. United States US: Diabetes Prevalence: % of Population Aged 20-79 data is updated yearly, averaging 10.790 % from Dec 2017 (Median) to 2017, with 1 observations. United States US: Diabetes Prevalence: % of Population Aged 20-79 data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s USA – Table US.World Bank: Health Statistics. Diabetes prevalence refers to the percentage of people ages 20-79 who have type 1 or type 2 diabetes.; ; International Diabetes Federation, Diabetes Atlas.; Weighted average;

Germany DE: Diabetes Prevalence: % of Population Aged 20-79 data was reported at 6.900 % in 2021. This records an increase from the previous number of 5.300 % for 2011. Germany DE: Diabetes Prevalence: % of Population Aged 20-79 data is updated yearly, averaging 6.100 % from Dec 2011 (Median) to 2021, with 2 observations. The data reached an all-time high of 6.900 % in 2021 and a record low of 5.300 % in 2011. Germany DE: Diabetes Prevalence: % of Population Aged 20-79 data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s Germany – Table DE.World Bank.WDI: Social: Health Statistics. Diabetes prevalence refers to the percentage of people ages 20-79 who have type 1 or type 2 diabetes. It is calculated by adjusting to a standard population age-structure.;International Diabetes Federation, Diabetes Atlas.;Weighted average;

Diabetes Management Market Outlook

The global diabetes management market size was valued at USD 58.4 billion in 2023 and is projected to reach USD 94.6 billion by 2032, growing at a CAGR of 5.3% during the forecast period. The increasing prevalence of diabetes worldwide, coupled with rising awareness about diabetes management and technological advancements in diabetes care devices, are significant growth factors driving this market. The aging population and lifestyle-related factors contributing to the rising incidence of diabetes further bolster market growth.

One of the primary growth factors for the diabetes management market is the escalating incidence and prevalence of diabetes globally. According to the International Diabetes Federation (IDF), approximately 537 million adults (20-79 years) were living with diabetes in 2021, a number projected to rise to 643 million by 2030. This alarming increase necessitates effective diabetes management solutions, propelling market growth. Additionally, the growing awareness about the long-term complications of diabetes and the importance of proper management is fueling the adoption of advanced diabetes care products and technologies.

Technological advancements in diabetes care devices are another critical factor contributing to market growth. Innovations such as continuous glucose monitoring (CGM) systems, artificial pancreas systems, and smart insulin pens have revolutionized diabetes management, improving patient outcomes and quality of life. The integration of digital health technologies, such as mobile applications and cloud-based platforms, with diabetes care devices allows for real-time monitoring and data sharing, enhancing diabetes management and patient compliance. These advancements are expected to continue driving the market during the forecast period.

The increasing adoption of diabetes management solutions in emerging markets presents significant growth opportunities. Countries in the Asia Pacific, Latin America, and Middle East & Africa regions are witnessing a surge in diabetes prevalence due to urbanization, changing lifestyles, and dietary habits. Government initiatives to improve healthcare infrastructure, increase awareness, and subsidize diabetes care products further support market growth in these regions. Additionally, the rising disposable incomes and growing middle-class population in these regions are driving the demand for advanced diabetes management solutions.

Regionally, North America dominated the diabetes management market in 2023, owing to the high prevalence of diabetes, well-established healthcare infrastructure, and favorable reimbursement policies. However, the Asia Pacific region is expected to witness the highest growth rate during the forecast period, driven by the increasing diabetic population, improving healthcare facilities, and rising awareness about diabetes management. Europe also holds a significant market share, supported by the high prevalence of diabetes and robust healthcare systems in countries like Germany, the UK, and France.

Product Type Analysis

The diabetes management market is segmented by product type into insulin, insulin delivery devices, blood glucose monitoring devices, continuous glucose monitoring devices, and others. Insulin remains a cornerstone in the treatment of diabetes, especially for Type 1 diabetes and advanced Type 2 diabetes. With the increasing prevalence of diabetes, the demand for insulin is expected to rise. Technological advancements in insulin formulations, such as long-acting and rapid-acting insulins, have improved patient compliance and outcomes, further driving the market growth.

Insulin delivery devices, including insulin pens, pumps, and jet injectors, have seen significant advancements in recent years. These devices offer ease of use, precision in insulin delivery, and improved patient compliance. Insulin pumps, in particular, have gained popularity due to their ability to provide continuous insulin infusion, mimicking the body's natural insulin release. The growing adoption of insulin delivery devices is driven by the rising diabetic population, technological advancements, and increased awareness about the benefits of these devices.

Blood glucose monitoring devices are essential for effective diabetes management, allowing patients to monitor their blood glucose levels regularly. The market for these devices includes blood glucose meters, test strips, lancets, and lancing devices. The increasing prevalence of diabetes and the growing awareness about the importance of regular blood glu

The number of diabetics worldwide in 2024 was almost *** million. That number is expected to grow until at least the year 2050. The projected number of diabetics is expected to reach around *** million by that time. With an increased number of diabetics, the prevalence of diabetes is also projected to increase to around ** percent by 2050. Diabetes prevalence globally Diabetes is a chronic disease that affects the production and use of insulin in the body which affects blood glucose. Diabetes comes in two types, type 1 and type 2, which require different types of medical treatments. Globally, China, followed by India, has the largest number of diabetics as of 2024. Despite having the highest number of diabetics, China is not among the countries with the highest prevalence. Pakistan, followed by the Marshall Islands, had the highest prevalence of diabetics worldwide as of 2024. Diabetes pharmaceuticals Treatment for diabetes includes insulin, a hormone that regulates blood glucose, and pills to help regulate the effectiveness of insulin. Treatment depends on the type of diabetes. Danish drug manufacturer Novo Nordisk is one of the leading diabetes care companies in the world. In 2024, Novo Nordisk generated around *** billion kroner in revenue from its diabetes care segment.

The dataset includes age-standardized estimates of the prevalence of diabetes mellitus (DM) and its associated risk factors. The data is derived from the Non-Communicable Disease Risk Factor Collaboration (NCD-RisC), a global network of health scientists and practitioners that aims to provide reliable and up-to-date information on the prevalence of non-communicable diseases and their risk factors.

The dataset includes information from 200 countries and territories and covers the period from 1980 to 2014. The data is presented in both male and female categories, and estimates are given for different age groups ranging from 20-79 years old. The data is standardized to account for differences in age distributions across countries and over time.

The average for 2021 based on 20 countries was 8.73 percent. The highest value was in Mexico: 16.9 percent and the lowest value was in Ecuador: 4.4 percent. The indicator is available from 2000 to 2021. Below is a chart for all countries where data are available.

The country projected to have the highest number of diabetics in 2050 is China, with some *** million people between the ages of 20 and 79 expected to be suffering from diabetes at that time. It is forecast that the number of adults with the condition in Pakistan will exceed that of the United States by 2050. Number of diabetics worldwide Diabetes is a condition that causes the pancreas to stop (or severely reduce) the production of insulin, a hormone needed to regulate blood sugar levels. Many people worldwide live with diabetes: in 2024, a total of almost *** million people had diabetes. This number is projected to reach an estimated ***** million by the year 2050. Global diabetes costs In 2024, just over************* U.S. dollars were spent on diabetes-related healthcare treatment worldwide. Of 2024’s global total, around ***** billion U.S. dollars were spent in the United States alone. Global healthcare expenditures for diabetes are expected to increase by ** billion U.S. dollars by 2050.

The Western Pacific region had the highest number of diabetics worldwide in 2024, with approximately 215 million people aged 20-79 suffering from the disease. This staggering figure underscores the global diabetes epidemic, which affected nearly 589 million individuals worldwide in 2024. The prevalence of diabetes is forecasted to rise to about 13 percent of the global population by 2050, highlighting the urgent need for improved prevention and treatment strategies. Regional disparities and future projections While the Western Pacific leads in absolute numbers, other regions also face significant diabetes burdens. Southeast Asia follows with 106.9 million diabetics, while the Middle East and North Africa have 84.7 million cases. Looking ahead, Africa is expected to see a 142 percent increase in diabetes cases from 2024 to 2050, while North America and the Caribbean may experience a 21 percent rise. China is anticipated to maintain its position as the country with the highest number of diabetics worldwide by 2050. Global health concerns and diabetes impact Diabetes remains a critical health issue globally, contributing to various complications such as cardiovascular disease and chronic kidney disease. In 2021, diabetes was the eighth leading cause of death worldwide. That year, around 1.62 million people died due to diabetes. The financial impact of diabetes is also significant and expected to increase in the coming decades.

China is the country with the highest number of diabetics worldwide, with around *** million people suffering from the disease. By the year 2050, it is predicted that China will have around *** million people with diabetes. Death from diabetes Diabetes is one of the leading causes of death worldwide, accounting for **** million deaths in 2021. Diabetes at least doubles one’s chance of dying prematurely, and many places in the world lack appropriate treatment options. The highest number of deaths from diabetes comes from the Western Pacific, where around *** million people died from the disease in 2024. Obesity One of the biggest risk factors for developing diabetes is being overweight or obese. Rates of obesity have increased in recent years in many countries around the world. In the United States, for example, it is estimated that around ** percent of the adult population was obese in 2023, compared to ** percent of the population in 2011.

San Marino Diabetes Prevalence: % of Population Aged 20-79 data was reported at 5.640 % in 2017. San Marino Diabetes Prevalence: % of Population Aged 20-79 data is updated yearly, averaging 5.640 % from Dec 2017 (Median) to 2017, with 1 observations. San Marino Diabetes Prevalence: % of Population Aged 20-79 data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s San Marino – Table SM.World Bank: Health Statistics. Diabetes prevalence refers to the percentage of people ages 20-79 who have type 1 or type 2 diabetes.; ; International Diabetes Federation, Diabetes Atlas.; Weighted average;

Indonesia: Diabetes prevalence, percent of population ages 20-79: The latest value from 2021 is 10.6 percent, an increase from 5.1 percent in 2011. In comparison, the world average is 8.60 percent, based on data from 195 countries. Historically, the average for Indonesia from 2011 to 2021 is 7.85 percent. The minimum value, 5.1 percent, was reached in 2011 while the maximum of 10.6 percent was recorded in 2021.

Argentina: Diabetes prevalence, percent of population ages 20-79: The latest value from 2021 is 5.4 percent, a decline from 5.5 percent in 2011. In comparison, the world average is 8.60 percent, based on data from 195 countries. Historically, the average for Argentina from 2011 to 2021 is 5.45 percent. The minimum value, 5.4 percent, was reached in 2021 while the maximum of 5.5 percent was recorded in 2011.

Haiti: Diabetes prevalence, percent of population ages 20-79: The latest value from 2021 is 8.9 percent, an increase from 6.6 percent in 2011. In comparison, the world average is 8.60 percent, based on data from 195 countries. Historically, the average for Haiti from 2011 to 2021 is 7.75 percent. The minimum value, 6.6 percent, was reached in 2011 while the maximum of 8.9 percent was recorded in 2021.

Brazil: Diabetes prevalence, percent of population ages 20-79: The latest value from 2021 is 8.8 percent, a decline from 10.1 percent in 2011. In comparison, the world average is 8.60 percent, based on data from 195 countries. Historically, the average for Brazil from 2011 to 2021 is 9.45 percent. The minimum value, 8.8 percent, was reached in 2021 while the maximum of 10.1 percent was recorded in 2011.

Trinidad and Tobago: Diabetes prevalence, percent of population ages 20-79: The latest value from 2021 is 12.7 percent, unchanged from 12.7 percent in 2011. In comparison, the world average is 8.60 percent, based on data from 195 countries. Historically, the average for Trinidad and Tobago from 2000 to 2021 is 13.17 percent. The minimum value, 12.7 percent, was reached in 2011 while the maximum of 14.1 percent was recorded in 2000.

Hong Kong: Diabetes prevalence, percent of population ages 20-79: The latest value from 2021 is 7.8 percent, an increase from 7.6 percent in 2011. In comparison, the world average is 8.60 percent, based on data from 195 countries. Historically, the average for Hong Kong from 2000 to 2021 is 9.17 percent. The minimum value, 7.6 percent, was reached in 2011 while the maximum of 12.1 percent was recorded in 2000.

Diabetic Test Strip Market Outlook

The global diabetic test strip market size is projected to grow from USD 15.4 billion in 2023 to USD 24.1 billion by 2032, at a compound annual growth rate (CAGR) of 4.9%. A significant growth factor driving this market is the escalating prevalence of diabetes globally, which necessitates continuous monitoring for effective disease management.

One of the foremost growth factors in the diabetic test strip market is the increasing incidence of diabetes worldwide. According to the International Diabetes Federation, approximately 537 million adults (20-79 years) were living with diabetes in 2021, and this number is projected to rise to 643 million by 2030 and 783 million by 2045. The rising prevalence is attributed to factors such as sedentary lifestyles, unhealthy diets, and an aging population, all of which contribute to the need for regular blood glucose monitoring, thereby propelling the demand for diabetic test strips.

Technological advancements in diabetes management solutions also serve as a significant growth driver. Innovations such as continuous glucose monitoring (CGM) systems and smartphone-compatible test strips are making diabetes management more convenient and efficient. These advancements not only improve the accuracy of blood glucose readings but also provide users with real-time data, enabling better control over their condition. The integration of test strips with digital health platforms for data tracking, sharing, and remote monitoring is expected to further boost market growth.

Government initiatives and awareness programs related to diabetes management are also playing a crucial role in market expansion. Many governments across the globe are implementing strategies to educate the public about diabetes prevention and management. Subsidies and insurance coverage for diabetes-related products, including test strips, are making these essential tools more accessible to a broader population. Such supportive policies are anticipated to drive market growth significantly over the forecast period.

The role of Glucose Test Strips in diabetes management cannot be overstated. These strips are a critical component of self-monitoring blood glucose (SMBG) systems, allowing individuals to measure their blood sugar levels conveniently at home or on the go. The ease of use and accessibility of glucose test strips empower patients to take proactive steps in managing their diabetes, helping to prevent complications and improve overall quality of life. As technology advances, the accuracy and reliability of these strips continue to improve, making them an indispensable tool for millions of people living with diabetes worldwide. The demand for glucose test strips is expected to rise as more people seek effective ways to manage their condition.

Regionally, North America holds the largest share of the diabetic test strip market, primarily due to the high prevalence of diabetes and the presence of major market players in the region. The Asia Pacific region is expected to witness the fastest growth, driven by rising diabetes cases, improving healthcare infrastructure, and increasing awareness about diabetes management. Europe also represents a significant market share, supported by a well-established healthcare system and growing diabetic population.

Product Type Analysis

The diabetic test strip market by product type is segmented into glucose oxidase, glucose dehydrogenase, and other enzyme strips. Glucose oxidase strips are among the most commonly used due to their reliability and accuracy in measuring blood glucose levels. These strips function by reacting with glucose in the blood, producing a measurable signal that indicates the glucose concentration. The advancements in the accuracy and shelf life of glucose oxidase strips are likely to sustain their dominance in the market.

Glucose dehydrogenase strips are gaining traction due to their higher specificity and less susceptibility to interference from other substances present in the blood. These strips are particularly beneficial for patients who are on medications or have varying blood components that may affect glucose readings. The increasing preference for glucose dehydrogenase strips is driven by their ability to provide more accurate readings in diverse conditions, thus contributing to the market growth.

Other enzyme strips, although constituting a smaller market segment,

Armenia AM: Diabetes Prevalence: % of Population Aged 20-79 data was reported at 5.600 % in 2021. This records a decrease from the previous number of 8.500 % for 2011. Armenia AM: Diabetes Prevalence: % of Population Aged 20-79 data is updated yearly, averaging 7.050 % from Dec 2011 (Median) to 2021, with 2 observations. The data reached an all-time high of 8.500 % in 2011 and a record low of 5.600 % in 2021. Armenia AM: Diabetes Prevalence: % of Population Aged 20-79 data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s Armenia – Table AM.World Bank.WDI: Social: Health Statistics. Diabetes prevalence refers to the percentage of people ages 20-79 who have type 1 or type 2 diabetes. It is calculated by adjusting to a standard population age-structure.;International Diabetes Federation, Diabetes Atlas.;Weighted average;

Back groundDiabetes is increasing at an alarming rate throughout the world and about 80% of diabetic cases live in low and middle income countries. Glycemic control is the most important predictor for diabetic related complications and deaths. Identifying factors associated with glycemic control help health care providers and patients to work in the areas that reduce risks of diabetic related complications and deaths.ObjectivesThe aim of this study is to assess the magnitude and factors associated with glycemic control among type 2 diabetic patients at Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia.MethodsHospital-based cross sectional study was conducted on 412 type 2 diabetic patients who were attending in diabetic clinics at Tikur Anbessa Specialized Hospital. Data were collected through structured interview questionnaire, and data abstraction format to collect information from each patient’s medical records from March to April, 2015. Data were entered and analyzed using SPSS version 20 statistical software. Both descriptive and inferential statistics were used to determine magnitude of glycemic control and factors associated with poor glycemic control.ResultMedian age of participants was 52 years old (IQR = 40–60 years old). From the study participants,51.7% were females. Median duration of living with diabetes since diagnosis was 10 years (IQR: 5–16 years). About 80% of the respondents had uncontrolled fasting blood glucose level. The factors which are significantly associated with poor glycemic control were longer duration of diabetes (AOR = 2.72 95%CI:1.16–6.32), and being on insulin therapy (AOR = 3.01 95% CI: 1.5–5.9).ConclusionA high proportion of patients had poor glycemic control. Longer duration of the disease, and being on drug regimen of insulin were associated with poor glycemic control. Appropriate attention should be given to patients with longer duration of disease and those who are on insulin therapy.

According to Cognitive Market Research, the global Diabetes Management Apps market size will be USD XX million in 2024. It will expand at a compound annual growth rate (CAGR) of 9.50% from 2024 to 2031.

North America held the major market share for more than 40% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of 7.7% from 2024 to 2031.
Europe accounted for a market share of over 30% of the global revenue with a market size of USD XX million.
Asia Pacific held a market share of around 23% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of 11.5% from 2024 to 2031.
Latin America had a market share of more than 5% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of 8.9% from 2024 to 2031.
Middle East and Africa had a market share of around 2% of the global revenue and was estimated at a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of 9.2% from 2024 to 2031.
The Digital Diabetes Management Types of Services category is the fastest growing segment of the Diabetes Management Apps industry

Market Dynamics of Diabetes Management Apps Market

Key Drivers for Diabetes Management Apps Market

Growing Prevalence of Diabetes to Boost Market Growth

A key driver of the diabetes management apps market is the increasing global prevalence of both Type 1 and Type 2 diabetes. According to the International Diabetes Federation (IDF), millions of individuals are diagnosed with diabetes each year, creating a rising demand for effective management tools. Currently, 537 million adults (aged 20-79) are living with diabetes, which equates to 1 in 10 people worldwide. This figure is projected to grow to 643 million by 2030 and 783 million by 2045. Notably, over 75% of adults with diabetes reside in low- and middle-income countries. In 2021, diabetes was responsible for 6.7 million deaths—equivalent to 1 death every 5 seconds—and accounted for at least USD 966 billion in health expenditures, a 316% increase over the past 15 years. Diabetes management apps provide a convenient solution for individuals to monitor blood glucose levels, track food intake, manage medications, and maintain physical activity.

Increasing Smartphone Penetration to Drive Market Growth

The widespread adoption of smartphones has provided an ideal platform for health apps, including diabetes management apps. According to the GSMA’s 2023 State of Mobile Internet Connectivity Report, 54% of the global population—around 4.3 billion people—now owns a smartphone. The global rollout of 4G and 5G networks has facilitated mobile broadband access, with over two-thirds (69%) of smartphone users on 4G-enabled devices and 17% on 5G-enabled devices, especially in advanced regions like North America and East Asia & Pacific. With increasing smartphone and mobile internet access, even in emerging markets, more people can download and use diabetes management apps for real-time health monitoring. This growing integration of healthcare into mobile devices, known as mHealth, is driving the development and adoption of diabetes management solutions.

Restraint Factor for the Diabetes Management Apps Market

Data Privacy and Security Concerns Will Limit Market Growth

One of the most significant barriers to the adoption of diabetes management apps is the growing concern over data privacy and security. These apps collect and store sensitive health information, including glucose levels, dietary habits, and medication schedules. Breaches in data security or inadequate data protection measures can result in personal health data being exposed or misused, leading to a lack of trust in these apps. Stringent data protection regulations, such as the General Data Protection Regulation (GDPR) in Europe and the Health Insurance Portability and Accountability Act (HIPAA) in the U.S., pose a challenge for app developers. Ensuring compliance with these regulations can be costly and time-consuming, potentially discouraging smaller developers from entering the market.

Impact of Covid-19 on the Diabetes Management Apps Market

COVID-19 led to a rapid expansion of telemedicine, with healthcare systems worldwide shifting to remote care to minimize in-person visits. For in...